ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Interventional effects of Tsantan Sumtang in ischemic heart disease: an integrated network pharmacology and metabolomics approach.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI driven network pharmacology: Multi-scale mechanisms of traditional Chinese medicine from molecular to patient analysis.Computational and structural biotechnology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The traditional Tibetan compound Tsantan Sumtang is frequently used in Tibetan and Mongolian medicine to treat ischemic heart disease (IHD). However, there are two main issues impeding its widespread use: the mechanism of action is unclear, and the pharmacodynamic substances are not well defined. The aim of the study is to use a metabolomics and network pharmacology approach to study the mechanism of Tsantan Sumtang in treating ischemic heart disease. An in vivo model of left anterior descending coronary artery ligation was constructed. Metabolomic analyses were performed upon serum samples to identify differences in metabolites, and network pharmacology was used to search for possible targets for the treatment of IHD. Molecular docking was performed to validate the identified key targets. The integration of network pharmacology and metabolomics was used to explore potential underlying mechanisms. Finally, the screened active compound, quercetin, underwent further investigation. Serum metabolomics identified 37 differential metabolites. Further analysis of the labelled metabolites revealed 20 pathways. Network pharmacology identified 216 common targets between Tsantan Sumtang and ischemic heart disease. The "drug-component-disease-target" network diagram further screened the core targets (TNF, AKT1, IL6, ALOX5, PTGS2) and the core compounds (beta-sitosterol, luteolin, kaempferol, quercetin, and alpha-linolenic acid). Molecular docking showed that the core compound was well aligned with the core target. Integration of metabolomics and network pharmacology identified four pathways, including the arachidonic acid pathway, laying a foundation for subsequent studies. Concurrently, experimental investigations revealed that quercetin exhibits an antimyocardial ischemic effect, thereby affirming its role as a pharmacodynamic agent. Tsantan Sumtang exerts therapeutic effects against IHD through "multi-component-multi-target-multi-pathway." Since the metabolism of arachidonic acid likely plays an important role, this information can be used as an entry point for subsequent research. Quercetin may serve as a significant medicinal compound, contributing notably to therapeutic applications.
Indexed as
Identifiers
40500380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.